MA51914A - Formes posologiques et procédés pour obtenir du bupropion énantiomériquement enrichi ou pur - Google Patents
Formes posologiques et procédés pour obtenir du bupropion énantiomériquement enrichi ou purInfo
- Publication number
- MA51914A MA51914A MA051914A MA51914A MA51914A MA 51914 A MA51914 A MA 51914A MA 051914 A MA051914 A MA 051914A MA 51914 A MA51914 A MA 51914A MA 51914 A MA51914 A MA 51914A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- dosage forms
- enantiomerically enriched
- pure bupropion
- obtaining enantiomerically
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862634718P | 2018-02-23 | 2018-02-23 | |
| US201962794469P | 2019-01-18 | 2019-01-18 | |
| US201962809480P | 2019-02-22 | 2019-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51914A true MA51914A (fr) | 2020-12-30 |
Family
ID=67688503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051914A MA51914A (fr) | 2018-02-23 | 2019-02-25 | Formes posologiques et procédés pour obtenir du bupropion énantiomériquement enrichi ou pur |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP3755312A4 (https=) |
| JP (3) | JP2021513998A (https=) |
| KR (3) | KR20240091043A (https=) |
| CN (2) | CN120827545A (https=) |
| AU (3) | AU2019223187B2 (https=) |
| BR (1) | BR112020017179A2 (https=) |
| CA (1) | CA3092076A1 (https=) |
| CL (1) | CL2020002166A1 (https=) |
| CR (1) | CR20200415A (https=) |
| EC (1) | ECSP20060179A (https=) |
| IL (2) | IL276871B2 (https=) |
| MA (1) | MA51914A (https=) |
| MX (2) | MX2020008704A (https=) |
| MY (1) | MY202993A (https=) |
| NI (1) | NI202000056A (https=) |
| NZ (1) | NZ767378A (https=) |
| PE (1) | PE20211752A1 (https=) |
| SG (1) | SG11202008056SA (https=) |
| WO (1) | WO2019165379A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL276871B2 (en) * | 2018-02-23 | 2024-11-01 | Axsome Therapeutics Inc | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11660274B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11291639B2 (en) | 2018-09-20 | 2022-04-05 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11660273B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| WO2021055124A1 (en) * | 2019-09-20 | 2021-03-25 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US20250073188A1 (en) | 2020-06-05 | 2025-03-06 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| US11717518B1 (en) | 2022-06-30 | 2023-08-08 | Antecip Bioventures Ii Llc | Bupropion dosage forms with reduced food and alcohol dosing effects |
| US12156914B2 (en) * | 2022-06-30 | 2024-12-03 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising bupropion and cysteine |
| US12036191B1 (en) | 2022-06-30 | 2024-07-16 | Antecip Bioventures Ii Llc | Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan |
| US11730706B1 (en) | 2022-07-07 | 2023-08-22 | Antecip Bioventures Ii Llc | Treatment of depression in certain patient populations |
| WO2025259728A1 (en) * | 2024-06-13 | 2025-12-18 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1051166A1 (en) * | 1998-01-29 | 2000-11-15 | Sepracor, Inc. | Pharmaceutical uses of optically pure (+) -bupropion |
| US6337328B1 (en) * | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
| WO2005016318A1 (en) * | 2003-08-08 | 2005-02-24 | Biovail Laboratories Inc. | Modified-release tablet of bupropion hydrochloride |
| WO2012118562A1 (en) * | 2011-03-02 | 2012-09-07 | Rhine Pharmaceuticals, Llc | Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations |
| US10080727B2 (en) * | 2013-11-05 | 2018-09-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US9198905B2 (en) * | 2013-11-05 | 2015-12-01 | Antecip Bioventures Ii Llc | Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects |
| US9474731B1 (en) * | 2013-11-05 | 2016-10-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| WO2015095713A1 (en) * | 2013-12-20 | 2015-06-25 | Deuterx, Llc | Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion |
| IL276871B2 (en) * | 2018-02-23 | 2024-11-01 | Axsome Therapeutics Inc | Dosage forms and methods for enantiomerically enriched or pure bupropion |
-
2019
- 2019-02-25 IL IL276871A patent/IL276871B2/en unknown
- 2019-02-25 CA CA3092076A patent/CA3092076A1/en active Pending
- 2019-02-25 KR KR1020247017593A patent/KR20240091043A/ko not_active Ceased
- 2019-02-25 EP EP19756920.5A patent/EP3755312A4/en active Pending
- 2019-02-25 BR BR112020017179-4A patent/BR112020017179A2/pt not_active Application Discontinuation
- 2019-02-25 IL IL313368A patent/IL313368A/en unknown
- 2019-02-25 AU AU2019223187A patent/AU2019223187B2/en active Active
- 2019-02-25 KR KR1020237017449A patent/KR20230075531A/ko not_active Ceased
- 2019-02-25 JP JP2020544420A patent/JP2021513998A/ja active Pending
- 2019-02-25 WO PCT/US2019/019445 patent/WO2019165379A1/en not_active Ceased
- 2019-02-25 CN CN202510967625.3A patent/CN120827545A/zh active Pending
- 2019-02-25 CN CN201980026874.5A patent/CN112087999A/zh active Pending
- 2019-02-25 KR KR1020207027256A patent/KR20210003091A/ko not_active Ceased
- 2019-02-25 MY MYPI2020004315A patent/MY202993A/en unknown
- 2019-02-25 SG SG11202008056SA patent/SG11202008056SA/en unknown
- 2019-02-25 NZ NZ767378A patent/NZ767378A/en unknown
- 2019-02-25 MX MX2020008704A patent/MX2020008704A/es unknown
- 2019-02-25 CR CR20200415A patent/CR20200415A/es unknown
- 2019-02-25 MA MA051914A patent/MA51914A/fr unknown
- 2019-02-25 PE PE2020001272A patent/PE20211752A1/es unknown
-
2020
- 2020-08-20 MX MX2023009281A patent/MX2023009281A/es unknown
- 2020-08-21 NI NI202000056A patent/NI202000056A/es unknown
- 2020-08-21 CL CL2020002166A patent/CL2020002166A1/es unknown
- 2020-09-23 EC ECSENADI202060179A patent/ECSP20060179A/es unknown
-
2022
- 2022-06-27 AU AU2022204521A patent/AU2022204521B2/en active Active
- 2022-08-04 JP JP2022124557A patent/JP2022153638A/ja active Pending
-
2024
- 2024-03-15 JP JP2024041381A patent/JP2024075655A/ja active Pending
- 2024-08-17 AU AU2024205858A patent/AU2024205858A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210003091A (ko) | 2021-01-11 |
| IL276871B1 (en) | 2024-07-01 |
| CR20200415A (es) | 2021-02-03 |
| IL276871B2 (en) | 2024-11-01 |
| CN120827545A (zh) | 2025-10-24 |
| AU2019223187B2 (en) | 2022-07-28 |
| CL2020002166A1 (es) | 2020-10-23 |
| JP2022153638A (ja) | 2022-10-12 |
| IL276871A (en) | 2020-10-29 |
| IL313368A (en) | 2024-08-01 |
| EP3755312A4 (en) | 2022-03-16 |
| NI202000056A (es) | 2021-01-11 |
| AU2019223187A1 (en) | 2020-09-17 |
| JP2021513998A (ja) | 2021-06-03 |
| CA3092076A1 (en) | 2019-08-29 |
| JP2024075655A (ja) | 2024-06-04 |
| KR20240091043A (ko) | 2024-06-21 |
| CN112087999A (zh) | 2020-12-15 |
| BR112020017179A2 (pt) | 2020-12-22 |
| WO2019165379A1 (en) | 2019-08-29 |
| ECSP20060179A (es) | 2020-12-31 |
| SG11202008056SA (en) | 2020-09-29 |
| AU2022204521A1 (en) | 2022-07-21 |
| AU2022204521B2 (en) | 2024-09-05 |
| MX2023009281A (es) | 2023-08-17 |
| KR20230075531A (ko) | 2023-05-31 |
| AU2024205858A1 (en) | 2024-09-05 |
| NZ767378A (en) | 2024-03-22 |
| EP3755312A1 (en) | 2020-12-30 |
| PE20211752A1 (es) | 2021-09-06 |
| MX2020008704A (es) | 2020-12-07 |
| MY202993A (en) | 2024-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51914A (fr) | Formes posologiques et procédés pour obtenir du bupropion énantiomériquement enrichi ou pur | |
| EP3847818A4 (en) | A VIDEO ENCODER, A VIDEO DECODER, AND CORRESPONDING METHODS | |
| EP3987794A4 (en) | ENCODER, DECODER AND METHOD THEREOF | |
| MA71705A (fr) | Substances et procédés pour le traitement d'hémoglobinopathies | |
| EP3861743A4 (en) | VIDEO DECODER AND METHOD | |
| MA50849A (fr) | Substances et procédés pour le traitement d'hémoglobinopathies | |
| EP4070549A4 (en) | ENCODER, DECODER AND RELATED METHODS AND DEVICE | |
| EP3975717C0 (en) | WATER TREATMENT PROCESS AND COMPOSITION | |
| EP3556222C0 (en) | SYSTEM AND METHOD FOR PRODUCING A SUGAR STREAM | |
| EP3552834A4 (en) | FRAME PLATE AND MANUFACTURING METHOD THEREOF | |
| EP3532042A4 (en) | METHOD FOR IMPROVING SYNAPTOGENESIS AND NEURITOGENESIS | |
| EP3864715A4 (en) | DISPLAY SUBSTRATE, DISPLAY APPARATUS AND METHOD OF MAKING DISPLAY SUBSTRATE | |
| EP3710422C0 (en) | PROCESS FOR PREPARING ENANTIOMERICALLY AND DIASTEROMERICALLY ENRICHED CYCLOBUTANE AMINES AND AMIDES | |
| EP4026337A4 (en) | ENCODER, DECODER AND METHOD THEREOF | |
| EP3461088A4 (en) | Method and apparatus for determining video quality, and method and apparatus for locating network fault | |
| EP3982633A4 (en) | VIDEO ENCODER, VIDEO DECODER AND CORRESPONDING METHOD | |
| EP4070551A4 (en) | ENCODER, DECODER AND METHOD THEREOF | |
| EP3960868A4 (en) | Polyhydroxyalkanoic acid and method for producing same | |
| EP3868110A4 (en) | CODERS, DECODERS AND RELATED METHODS FOR UNBLOCKING FILTER ADAPTATION | |
| EP3527191A4 (en) | COMPOSITE DENTAL RESIN MATERIAL, METHOD FOR PRODUCING COMPOSITE DENTAL RESIN MATERIAL, AND POLYARYLETHERCETONE RESIN FOR PRODUCING COMPOSITE DENTAL RESIN MATERIAL | |
| EP3781137A4 (en) | HUMIDITY RESISTANT PROBIOTIC GRANULE AND ITS PRODUCTION PROCESSES | |
| EP3896974A4 (en) | Video encoder, video decoder, and corresponding method | |
| EP4076881C0 (de) | Vorrichtung zur herstellung von betonsteinen | |
| EP3837845A4 (en) | VIDEO ENCODER, VIDEO DECODER AND RELEVANT PROCEDURE | |
| EP3686306A4 (en) | SHEET STEEL, AND METHOD OF MANUFACTURING THE SAME |